Could CAR-T cells tame tough lupus kidney disease?
NCT ID NCT05938725
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new treatment called KYV-101, which uses a patient's own modified immune cells (CAR-T cells) to target and destroy faulty B cells that drive lupus kidney inflammation. The study involves 6 adults with lupus nephritis that hasn't responded to standard therapies. Researchers are primarily checking for safety and side effects, while also looking for signs that the treatment can improve kidney function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KYV-101 anti-CD19 CAR-T cell therapy
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat lupus kidney disease, potentially reducing the need for long-term immunosuppression.
What could go wrong
This is a very early, small trial with only 6 participants, so results may not apply widely. CAR-T therapy carries risks like severe immune reactions and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwell Health
Great Neck, New York, 11021, United States
-
Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
Stanford University Medical Center
Palo Alto, California, 94305, United States
-
University of Colorado
Denver, Colorado, 80045, United States
-
University of Massachusetts Worcester
Worcester, Massachusetts, 01655, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States